FDA Approves First Targeted Therapy for HER2-Low Breast Cancer

MONDAY, Aug. 8, 2022 -- The U.S. Food and Drug Administration has approved Enhertu (am-trastuzumab-deruxtecan-nxki), an intravenous infusion treatment for patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-low...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news